Pectasides D, Yianniotis H, Alevizakos N, Bafaloukos D, Barbounis V, Varthalitis J, Dimitriadis M, Athanassiou A
Department of Medical Oncology, Metaxas Memorial Cancer Hospital, Piraeus, Greece.
Br J Cancer. 1989 Oct;60(4):627-9. doi: 10.1038/bjc.1989.327.
Twenty-seven patients with disseminated malignant melanoma were treated monthly with cisplatin (CDDP) 120 mg m-2 on day 1, vindesine (VDS) 3 mg m-2 on day 2 and dacarbazine (DTIC) 250 mg m-2 on days 2-6. None of them had received prior chemotherapy. All patients are evaluable for response and toxicity. There were five (19%) complete (CR) and seven (26%) partial (PR) responses for a total response rate of 45%. We conclude that the combination of DTIC, VDS and CDDP is capable of producing a relatively high rate of response in patients with advanced metastatic malignant melanoma, but responses are short.
27例播散性恶性黑色素瘤患者接受如下治疗：第1天给予顺铂（CDDP）120 mg/m²，第2天给予长春地辛（VDS）3 mg/m²，第2 - 6天给予达卡巴嗪（DTIC）250 mg/m²，每月1次。所有患者此前均未接受过化疗。所有患者均可评估疗效及毒性。有5例（19%）完全缓解（CR），7例（26%）部分缓解（PR），总缓解率为45%。我们得出结论，DTIC、VDS和CDDP联合应用能够使晚期转移性恶性黑色素瘤患者产生相对较高的缓解率，但缓解持续时间较短。
